WallStSmart

Biodesix Inc (BDSX)vsIQVIA Holdings Inc (IQV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

IQVIA Holdings Inc generates 17573% more annual revenue ($16.98B vs $96.10M). IQV leads profitability with a 8.1% profit margin vs -33.3%. IQV earns a higher WallStSmart Score of 55/100 (C).

BDSX

Avoid

29

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 4.0Quality: 4.5
Piotroski: 4/9Altman Z: -7.79

IQV

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 6.7Quality: 3.0
Piotroski: 2/9Altman Z: 1.23
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BDSXSignificantly Overvalued (-15.9%)

Margin of Safety

-15.9%

Fair Value

$8.93

Current Price

$23.50

$14.57 premium

UndervaluedFair: $8.93Overvalued
IQVUndervalued (+11.9%)

Margin of Safety

+11.9%

Fair Value

$201.09

Current Price

$238.70

$37.61 discount

UndervaluedFair: $201.09Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDSX1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
42.3%10/10

Revenue surging 42.3% year-over-year

IQV2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.3%9/10

Every $100 of equity generates 22 in profit

PEG RatioValuation
0.988/10

Growing faster than its price suggests

Areas to Watch

BDSX4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$221.51M3/10

Smaller company, higher risk/reward

Price/BookValuation
26.1x2/10

Trading at 26.1x book value

Return on EquityProfitability
-349.9%2/10

ROE of -349.9% — below average capital efficiency

IQV4 concerns · Avg: 2.8/10
P/E RatioValuation
29.2x4/10

Moderate valuation

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-0.6%2/10

Earnings declined 0.6%

Altman Z-ScoreHealth
1.232/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BDSX

The strongest argument for BDSX centers on Revenue Growth. Revenue growth of 42.3% demonstrates continued momentum.

Bull Case : IQV

The strongest argument for IQV centers on Return on Equity, PEG Ratio. PEG of 0.98 suggests the stock is reasonably priced for its growth.

Bear Case : BDSX

The primary concerns for BDSX are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 7.84 is elevated, increasing financial risk.

Bear Case : IQV

The primary concerns for IQV are P/E Ratio, Piotroski F-Score, EPS Growth. Debt-to-equity of 2.58 is elevated, increasing financial risk.

Key Dynamics to Monitor

BDSX profiles as a hypergrowth stock while IQV is a value play — different risk/reward profiles.

IQV carries more volatility with a beta of 1.20 — expect wider price swings.

BDSX is growing revenue faster at 42.3% — sustainability is the question.

IQV generates stronger free cash flow (491M), providing more financial flexibility.

Bottom Line

IQV scores higher overall (55/100 vs 29/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Biodesix Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company is headquartered in Boulder, Colorado.

IQVIA Holdings Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.

Want to dig deeper into these stocks?